By contrast, cardiometabolic comorbidities were more frequently documented in the university hospital cohort, with higher rates of dyslipidemia (80.0% vs. 43.8%, p < 0.001) and hypertension (89.1% vs. 70.0%, p = 0.016), as well as greater use of concomitant therapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RA) (36.4% vs. 7.5%, p < 0.001) and renin–angiotensin–aldosterone system (RAAS) inhibitors (81.8% vs. 61.3%, p = 0.018). Here, GLP1R is linked to metabolic syndrome.